BCMA/CD70 Dual CAR T / Allogene Therap - LARVOL DELTA

Preclinical evaluation of allogeneic BCMA/CD70 Dual CAR T cells for high-risk multiple myeloma (AACR 2026) - "Compared with single targeting BCMA CAR T cells, BCMA/CD70 Dual CAR T cells showed improved cytotoxic activity and expansion in an in vitro model of antigen-escape.Taken together, these results demonstrate that BCMA/CD70 Dual CAR T cells produced using site-specific integration show specific cytotoxic activity, rejection avoidance, and the ability to eliminate tumor cells that have downregulated BCMA. Our findings underscore the promise of allogeneic BCMA/CD70 Dual CAR T cells as an accessible, off-the-shelf treatment option for high-risk multiple myeloma patients and those who have progressed after BCMA-directed therapies, with the potential to extend beyond multiple myeloma toward broader applications in autoimmune disorders."

CAR T-Cell Therapy • IO biomarker • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology • CD70 • IFNG • IL2 • TNFA